Factor Xa Inhibition in the Management of Venous Thromboembolism: Important Safety Information. Important Safety Information (cont d)
|
|
- Phyllis Norris
- 6 years ago
- Views:
Transcription
1 Factor Xa Inhibition in the Management of Venous Thromboembolism: The Role of Fondaparinux WARNING: SPINAL/EPIDURAL HEMATOMAS Epidural or spinal hematomas may occur in patients who are anticoagulated with low molecular weight heparins (LMWH), heparinoids, or fondaparinux sodium and are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include: use of indwelling epidural catheters concomitant use of other drugs that affect hemostasis, such as nonsteroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, or other anticoagulants a history of traumatic or repeated epidural or spinal puncture a history of spinal deformity or spinal surgery Monitor patients frequently for signs and symptoms of neurologic impairment. If neurologic compromise is noted, urgent treatment is necessary. Consider the benefit and risks before neuraxial intervention in patients anticoagulated or to be anticoagulated for thromboprophylaxis. XRA9R Important Safety Information CONTRAINDICATIONS ARIXTRA is contraindicated in the following conditions: Severe renal impairment (creatinine clearance < ml/min) in prophylaxis or treatment of venous thromboembolism. Active major bleeding. Bacterial endocarditis. Thrombocytopenia associated with a positive in vitro test for antiplatelet antibody in the presence of fondaparinux sodium. Body weight < kg (venous thromboembolism prophylaxis only). Important Safety Information (cont d) WARNINGS AND PRECAUTIONS Use with caution in patients who have conditions or who are taking concomitant medications that increase risk of hemorrhage. Bleeding risk is increased in renal impairment and in patients with low body weight. Thrombocytopenia can occur with administration of ARIXTRA. Periodic routine complete blood counts (including platelet counts), serum creatinine level, and stool occult blood tests are recommended The packaging (needle guard) contains dry natural rubber and may cause allergic reactions in latex sensitive individuals
2 Incidence and Consequences of Venous Thromboembolism (VTE) Incidence More than, hospitalizations occur each year due to VTE % of hospital deaths can be attributed to pulmonary embolism (PE) per year Overall mortality rate within month of diagnosis % for PE Consequences % for deep vein thrombosis (DVT) Acute PE Recurrent VTE : Highest within first - months 7% within years following initial treatment % within years following initial treatment Post-thrombotic syndrome (PTS). Rosamond W et al. Circulation. 8;7:e-e.. Heit JA. J Thromb Haemost. ;:-7.. Prandoni P et al. Haematologica. 997;8:-8.. Bradjes DPM. Lancet. 997;9:79-7. The Joint Commission on Accreditation of Healthcare Organizations (JCAHO) and National Quality Forum (NQF) Measures VTE is preventable and it is the most common preventable cause of hospital death. JCAHO/NQF VTE Measures Effective Screening Prevention Treatment JCAHO and NQF have paired to provide a framework of measures for effective screening, prevention, and treatment for persons at risk of VTE. NQF VTE Measures 8. Accessed February,.. NQF Project Brief. Accessed February,. Patient Characteristics and Surgical Risk Factors for VTE VTE Patient Characteristics, Surgical Risk Factors Major surgery Prolonged immobility Previous VTE Obesity Varicose veins Increasing age Paralysis Smoking Pregnancy Estrogen use Malignancy Cancer therapy Procedure Duration of procedure Surgical site Surgical technique Anesthesia Presence of infection Postoperative immobilization. Geerts WH et al. Chest. ;( suppl):8s-s.. Heit JA et al. Arch Intern Med. ;: Geerts WH et al. Chest. ;9( suppl):s-7s.
3 Mechanisms of Anticoagulation Intrinsic system (surface contact) XII XI XIIa XIa Extrinsic system (tissue damage) Tissue factor IX IXa VIIa VII Unfractionated heparin, VIII Low molecular-weight heparins, VIIIa X Xa Vitamin K antagonists Direct thrombin inhibitors, Factor Xa inhibitors, V Va II Fibrinogen IIa (Thrombin) Fibrin. Adapted with permission from Petitou M et al. Nature. 99;(9 suppl):-.. Hirsh J, Fuster V. Circulation. 99;89:9-8.. Hirsh J et al. Chest. ;9( suppl):s-9s.. Nutescu EA et al. Pharmacotherapy. ;(7 Pt ):8S-87S.. Bauer KA. J Thromb Thrombolysis. ;: ARIXTRA (fondaparinux sodium) Is a Nonheparin, Selective Factor Xa Inhibitor Intrinsic pathway Extrinsic pathway AT AT AT Xa Xa II IIa Fibrinogen ARIXTRA reversibly binds AT, causing a conformational change Fibrin clot AT affinity for Factor Xa increases, enhancing inhibitory effect of AT by X Thrombin (IIa) generation is inhibited, leading to reduced thrombus development AT: antithrombin. : ARIXTRA. Adapted from Turpie AG et al. N Engl J Med. ;:9-. Prescribing Information for ARIXTRA. 8 Differentiating Biochemical Properties of ARIXTRA First and only FDA-approved selective Factor Xa inhibitor Unique mechanism of action ARIXTRA acts selectively on Factor Xa Small, synthetic compound Small size prevents interaction with thrombin Made exclusively by chemical synthesis NOT derived from animal sources, Batch-to-batch consistency Not made from any heparin products. Lassen et al. Lancet. ;9:7-7.. Comp PC. Pharmacotherapy. ;: Data on file, GlaxoSmithKline. 9
4 Biochemical Properties of ARIXTRA Inhibition of thrombin generation (%) 7 ARIXTRA Effectively Inhibits Thrombin Generation Anti-Factor Xa (units/ml) Factor Xa inhibition results in linear, dose-dependent inhibition of thrombin generation Nonheparin anticoagulant with a rapid onset of action Provides patients a quick anticoagulant response Allows once-daily dosing without aptt monitoring Concentration of ARIXTRA (µg/ml) Rapid Onset of Action of ARIXTRA T max C max Half-life hours. µg/ml 7 to hours Bioavailability % 8 8 Time (hours) aptt = activated partial thromboplastin time.. Adapted with permission from Lormeau JC, Herault JP. Thromb Haemost. 99;7: Donat F et al. Clin Pharmacokinet. ;(suppl ):-9. Benefits of ARIXTRA ARIXTRA is the st available FDA-approved, nonheparin, injectable anticoagulant ARIXTRA Always dosed once-daily Synthetic, nonheparin compound Specific Factor Xa inhibition Rapid onset of action Does not inactivate thrombin st FDA-approved in unique class Important Safety Information ARIXTRA is contraindicated in the following conditions: Severe renal impairment (creatinine clearance < ml/min) in prophylaxis or treatment of venous thromboembolism. Body weight < kg (venous thromboembolism prophylaxis only). Bleeding risk is increased in renal impairment and in patients with low body weight.
5 Clinical Development of ARIXTRA in PE and DVT: Evaluated in More Than, Patients Indication Trial Population Comparator Orthopedic surgery No. randomized Year completed Penthifra Hip fracture Enoxaparin Penthifra Plus Hip fracture extended prophylaxis Placebo Pentathlon Hip replacement Enoxaparin 7 Ephesus Hip replacement Enoxaparin 9 Pentamaks Knee replacement Enoxaparin 9 Abdominal surgery Treatment of acute VTE PEGASUS Abdominal Dalteparin 97 surgery* APOLLO Abdominal IPC ± ES 9 surgery* MATISSE DVT Acute DVT Enoxaparin MATISSE PE Acute PE UFH *In patients at high risk of VTE. IPC = Intermittent pneumatic compression. ES = Elastic stockings. 8 ACCP Guidelines for Antithrombotic and Thrombolytic Therapy The American College of Chest Physicians (ACCP) has successfully provided high-quality clinical practice guidelines for over years Extensive review of literature for management of thromboembolic disorders Grading system has been revised for the purposes of consistency and comparison with other guidelines Less confusion compared with other recommendations This grading system is used by many organizations: American College of Physicians American Thoracic Society World Health Organization Clinicians are most interested in the best course of action when considering a treatment, therefore the strength of the recommendation is integrated into the grading system. Baumann MH, Gutterman DD. Chest. ;9:-;. Hirsh et al. Chest. 8;:7S-9S;. Guyatt GH et al. Chest. 8;S-S. ACCP Grades of Recommendation Strength of recommendation is determined by considering the benefit vs the harm and the quality of evidence Grade : Strong recommendation indicating that benefits outweigh the harms, burdens, or costs Grade : Weaker recommendation, less certainty of benefits Grade A: Quality, randomized, controlled trials with unbiased results Grade B: Randomized, controlled trials with inconsistent results, poor study design, and/or biased results Grade C: Low-quality evidence or observational studies Guyatt GH et al. Chest. 8;S-S.
6 Summary of ACCP Recommendations VTE treatment Fondaparinux LMWH UFH VKA Treatment of DVT (When administered in conjunction with warfarin) Treatment of PE (When administered in conjunction with warfarin and when initial therapy is started in the hospital) VTE prophylaxis A A A * A A A * Elective hip replacement A A Elective knee replacement A A Hip fracture surgery A B Hip fracture surgery with extended prophylaxis Abdominal surgery (In patients at risk of thromboembolic complications) B (LDUH) A (adjusted dose) A (adjusted dose) B (adjusted dose) A C C A A A (LDUH) * When used in conjunction with warfarin. Abdominal surgery indication is included generally in section.. and.. in ACCP guidelines regarding general surgery on pages 9S-9S. Hirsh et al. Chest. 8;:7S-9S. 8 Recommendations for the Treatment of Venous Thromboembolism (VTE) A grade of A signifies a strong recommendation based on high-quality evidence Treatment of Deep Vein Thrombosis (DVT) In patients with acute DVT, fondaparinux, low molecular-weight heparin (LMWH), or unfractionated heparin (UFH) in combination with vitamin K antagonist (VKA) are recommended for treatment with a grade of A In patients with acute DVT, initiation of a VKA plus ARIXTRA, LMWH, or UFH is recommended on the first treatment day rather than delayed initiation of VKA (Grade A) Treatment of Pulmonary Embolism (PE) Fondaparinux, LMWH, or UFH in combination with VKA are recommended for the treatment of confirmed PE with a grade of A In patients with acute PE, initiation of a VKA plus ARIXTRA, LMWH, or UFH is recommended on the first treatment day rather than delayed initiation of VKA (Grade A) Hirsh et al. Chest. 8;:7S-9S. 7 MATISSE Studies: ARIXTRA for the Treatment of PE and DVT Objectives: Noninferiority studies designed to demonstrate the effectiveness of ARIXTRA in the treatment of PE and DVT, Primary efficacy outcome: incidence of symptomatic recurrent VTE during -month study period Primary safety outcome: incidence of major bleeding during initial treatment period PE study To evaluate the efficacy and safety of subcutaneous ARIXTRA QD compared with intravenous UFH in the treatment of acute, symptomatic PE DVT study To evaluate the efficacy and safety of ARIXTRA QD compared with enoxaparin BID in the treatment of acute, symptomatic DVT. Büller HR et al. N Engl J Med. ;9:9-7.. Büller HR et al. Ann Intern Med. ;:
7 MATISSE PE Study: Study Design Randomized, Open-label, Multicenter Study Eligibility and randomization (n = ) ARIXTRA (., 7., or. mg) daily* (n = ) Treatment continued for at least days Vitamin K antagonists (started within 7 hours of treatment and continued for up to months) *. mg in patients < kg 7. mg in patients kg kg. mg in patients > kg UFH IU IV bolus followed by IU/ hour continuous IV infusion (n = ) Treatment continued for at least days Vitamin K antagonists (started within 7 hours of treatment and continued for up to months) Until the international normalized ratio was >. for consecutive days. Büller HR et al. N Engl J Med. ;9: MATISSE PE Study: Patient Characteristics Characteristic ARIXTRA (n = ) UFH (n = ) Mean age, yr ±. ±.7 Male/female / 77/ Mean body weight, kg 8 ± ± 9. Previous VTE 9 (.7%) (.%) Known prothrombotic state 8 (.%) (.7%) Surgery or trauma (< months ago) 8 (.%) (.%) Büller HR et al. N Engl J Med. ;9:9-7. MATISSE PE Study: ARIXTRA Was at Least as Effective as UFH in Treating PE Patients with recurrent venous thromboembolic events (%).8 An absolute difference of -. (9% CI -. to.) for all recurrent VTE shows ARIXTRA was as effective as UFH P = NS ARIXTRA (n = )... UFH (n = )... n = n = n = n = 7 n = n = n = n = All VTE DVT only Fatal PE Nonfatal PE. Primary outcome Secondary outcomes NS = not significant. Patients were also treated with vitamin K antagonist within 7 hours after the first administration of the study drug; VTE was a composite of symptomatic, recurring, nonfatal VTE, or fatal PE occurring throughout entire study.. Büller HR et al. N Engl J Med. ;9:9-7. 7
8 MATISSE DVT Study: Study Design Double-blind, Randomized, Multicenter Study Eligibility and randomization (n = ) ARIXTRA (., 7., or. mg) daily* (n = 98) Treatment continued for at least days Vitamin K antagonists (started within 7 hours of treatment and continued for up to months) Enoxaparin ( mg/kg) BID (n = 7) Treatment continued for at least days Vitamin K antagonists (started within 7 hours of treatment and continued for up to months) *. mg in patients < kg 7. mg in patients kg kg. mg in patients > kg Until the international normalized ratio was >. for consecutive days. Büller HR et al. Ann Intern Med. ;: MATISSE DVT Study: Patient Characteristics Characteristic ARIXTRA (n = 98) Enoxaparin (n = 7) Mean age, yr. ±.7. ±. Male/female 8/7 78/9 Mean body weight, kg 79. ± ± 7. Previous VTE 7 (.9%) 8 (.%) Known prothrombotic state 8 (.%) (.7%) Surgery or trauma (< months ago) (.9%) (.7%) Büller HR et al. Ann Intern Med. ;: MATISSE DVT Study: ARIXTRA Was at Least as Effective as Enoxaparin in Treating DVT Patients with recurrent venous thromboembolic events (%) An absolute difference of -. (9% CI -.8 to.) for all recurrent VTE shows ARIXTRA is as effective as enoxaparin P = NS... ARIXTRA (n = 98) Enoxaparin (n = 7).. n = n = n = 8 n = 8 n = n = n = n = All VTE DVT only Fatal PE Nonfatal PE.8. Primary outcome Secondary outcomes VTE was a composite of symptomatic, recurring, nonfatal VTE, or fatal PE occurring throughout entire study.. Büller HR et al. Ann Intern Med. ;:
9 Patients (%) ARIXTRA Had Major Bleeding Rates Similar to UFH/ Enoxaparin in Patients With PE/DVT 8 Absolute difference (9% CI). P = NS... Patients (%) n = n = n = 9 n = 9 n = n = n = n = Major bleeding. (-.7 to.) Major bleeding* results from Pegasus and APOLLO MATISSE PE ARIXTRA (N = 9) UFH (N = 9) P = NS Major and nonmajor bleeding -.8 (-.7 to.) 8. P = NS. Major bleeding -. (-. to.8) Bleeding during initial treatment is shown. MATISSE DVT ARIXTRA (N = 9) Enoxaparin (N = ) P = NS.7. Major and nonmajor bleeding -. (-. to.) * Major bleeding was defined as being clinically apparent and associated with a decrease of g/dl or more in the hemoglobin level, leading to the transfusion of or more units of red cells or whole blood, being retroperitoneal or intracranial, occurring in a critical organ, or contributing to death. Mean duration of initial treatment in MATISSE PE study:. days ±. ARIXTRA;.9 ±. days UFH. Mean duration of initial treatment in MATISSE DVT study: 7. days ±. ARIXTRA; 7. days ±. enoxaparin.. Büller HR et al. N Engl J Med. ;9:9-7.. Büller HR et al. Ann Intern Med. ;: ARIXTRA for the Prophylaxis of VTE: In Patients Following Major Orthopedic Surgery* and at Risk Undergoing Abdominal Surgery *Major orthopedic surgery included elective hip replacement, hip fracture, and knee replacement surgeries. At-risk patients were > years of age, or between the ages of and years, with or more additional risk factors for VTE or who were undergoing abdominal surgery with general anesthesia expected to last > minutes. 8 Recommendations for Orthopedic Surgery Elective Hip Replacement Fondaparinux, LMWH, or adjusted-dose VKA are recommended as an anticoagulant option for elective hip replacement surgery with a grade of A Elective Knee Replacement Fondaparinux, LMWH, or adjusted-dose VKA are recommended for thrombophylaxis for elective knee replacement surgery with a grade of A Hirsh et al. Chest. 8;:7S-9S. 7 9
10 8 Recommendations for Orthopedic Surgery Hip Fracture Surgery For hip fracture surgery, fondaparinux received a recommendation with a grade of A for thrombophylaxis, while LMWH, LDUH, and adjusted-dose VKA both received grades of B Hip Fracture Surgery with Extended Prophylaxis Extended thrombophylaxis ( days up to days after surgery) for hip fracture surgery is recommended using fondaparinux (Grade A), LMWH (Grade C), or VKA (Grade C) Hirsh et al. Chest. 8;:7S-9S. 8 ARIXTRA Significantly Reduced the Rate of VTE Compared With Enoxaparin Following Major Orthopedic Surgery* Incidence of venous thromboembolic events up to Day (%) 8 ARIXTRA Reduced the Rate of VTE by.%.8 *Major orthopedic surgery included elective hip replacement, hip fracture, and knee replacement surgeries. In of the studies, ARIXTRA reduced the rate of VTE by %, %, and % vs enoxaparin (P<.). - In the fourth study, ARIXTRA reduced VTE by % vs enoxaparin (P = NS). Individual study data not shown. ARIXTRA is contraindicated in patients < kg for VTE prophylaxis..turpie AG et al. Arch Intern Med. ;:8-8.. Eriksson BI et al. N Engl J Med. ;:98-.. Bauer KA et al. N Engl J Med. ;:-.. Lassen MR et al. Lancet. ;9:7-7.. Turpie AG et al. Lancet. ;9:7-7. P <..7 (8/ 8) (7/ 7). (7/ 77). (/ 98) ARIXTRA Enoxaparin VTE DVT Proximal DVT Distal DVT Primary outcome Secondary outcomes A meta-analysis of randomized, double-blind clinical trials. (/ 7).9 (8/ 77. (/ 7).8 (9/ 79 9 Positive Bleeding Index Largely Accounts for Higher Bleeding Incidence* ARIXTRA (N = ) Enoxaparin (N = ) Patients (%) n = n = 9 n = n = 8 n= n = n = 8 n = n = n = Major bleeding Bleeding Led to Critical Fatal in perioperative index of re-operation organ prophylaxis trials Type of Major Bleeding *Perioperative orthopedic prophylaxis (Day to Day 7 ± postsurgery). Does not include extended prophylaxis (Day 8 to Day 8 ± postsurgery). Bleeding Index is calculated as the number of packed red blood cells or whole blood transfused plus prebleeding minus postbleeding hemoglobin (g/dl) values. Turpie AG et al. Arch Intern Med. ;:8-8.
11 Proper Timing of First Injection ( to 8 hours) Following Surgery Significantly Reduced Incidence of Major Bleeding.8 Patients with a bleeding index (%)...8. (/) (/89) (/7) (/) (9/9) Time from surgical closure to first injection (hours) Efficacy of ARIXTRA was not affected by injection timing (P =.7) When given hours after surgery, in accordance with prophylaxis recommendations, the incidence of major bleeding with ARIXTRA was reduced Adapted from Kwong LM, Muntz JE. Am J Orthop. ;(suppl ):-. 8 Recommendations for General Surgery General Surgery With Risk Characteristics Fondaparinux, LMWH, or LDUH are recommended for thromboprophylaxis in patients in benign disease at moderate risk undergoing general surgery with a grade of A For patients at higher risk during general surgery in cancer patients, fondaparinux, LMWH, or LDUH tid are recommended for thromboprophylaxis with a grade of A Please note: While the guidelines recommend fondaparinux for general surgery, ARIXTRA is not FDA-approved for general surgery. ARIXTRA is indicated for the prophylaxis of VTE in patients undergoing abdominal surgery at risk of thromboembolic complications. Abdominal surgery indication is included generally in section.. and.. in ACCP guidelines regarding general surgery on pages 9S-9S. Hirsh et al. Chest. 8;:7S-9S. PEGASUS Study: Study Design Randomized, Double-blind Clinical Trial ARIXTRA (. mg) QD (n = ) Eligibility and randomization (n = 8) Start hours post-op Double-blind Treatment 7 ± days Inclusion criteria High-risk* abdominal surgery under general anesthesia Surgery duration > min (incision to closure) Dalteparin IU pre-op and post-op IU once-daily post-op (n = ) Start hours pre-op Venogram Day - Follow-up Day ± *Age > years with or without additional risk factor for VTE; or age > years with at least additional risk factor for VTE. For VTE prophylaxis, ARIXTRA is contraindicated in patients < kg undergoing surgery. Agnelli G et al. Br J Surg. ;9:-.
12 APOLLO Study: Study Design Randomized, double-blind clinical trial with ARIXTRA in combination with mechanical prophylaxis ARIXTRA (. mg) QD + IPC ± ES (n = ) Eligibility and randomization (n = 9) Prophylaxis up to 7 ± days Start ARIXTRA or placebo -8 hr postoperatively (QD) after incision closure and established hemostasis Placebo + IPC ± ES (n = 9) Inclusion criteria Patients > yrs and > kg undergoing abdominal surgery Surgery duration > min (incision to closure) Venogram Day - Follow-up Day ± For VTE prophylaxis, ARIXTRA is contraindicated in patients < kg undergoing surgery. Turpie AG et al. J Thromb Haemost. 7;:8-8. ARIXTRA Provided Proven Protection From VTE in Patients at High Risk* Undergoing Abdominal Surgery Patients with venous thromboembolic events (%) 7 PEGASUS APOLLO ARIXTRA (n = 7) Dalteparin (n = ).. Patients with venous thromboembolic events (%) n = 7 n = n = 7 n = VTE VTE ARIXTRA was as effective as dalteparin in the prevention of VTE ARIXTRA in combination with IPC reduced the risk of VTE 7 ARIXTRA (n = ) Placebo (n = 8) P =...7 *> years with or without additional risk factors for VTE, or > years with at least one additional risk factor for VTE, and undergoing abdominal surgery with general anesthesia expected to last > minutes.. Agnelli G et al. Br J Surg. ;9:-.. Turpie AG et al. J Thromb Haemost. 7;:8-8. Major Bleeding Results from PEGASUS and APOLLO in Patients at High Risk Undergoing Abdominal Surgery Patients (% PEGASUS APOLLO ARIXTRA (n = ) Dalteparin (n = ) ARIXTRA (n = ) Placebo (n = ) P =... Patients (%) P =.. n = 9 n =. n = n = Major bleeding * Major bleeding * 97.% of patients who received ARIXTRA were free from major bleeding when the dose was administered hours after surgery. *During the treatment period: from the first injection -8 hours after surgery to days following last injection. Major bleeding was defined as any of the following: fatal, retroperitoneal, intracranial, intraspinal, or involving any other critical organ leading to intervention; bleeding at the surgical site leading to intervention; and/or with a bleeding index.. Agnelli G et al. Br J Surg. ;9:-.. Turpie AG et al. J Thromb Haemost. 7;:8-8.
13 FDA-Approved VTE-related Indications for ARIXTRA FDA-approved indication ARIXTRA Enoxaparin Treatment of PE, including outpatient - When administered in conjunction with warfarin and initiated in the hospital Treatment of DVT, including outpatient - When administered in conjunction with warfarin Abdominal surgery prophylaxis - In patients at risk for thromboembolic complications Knee replacement prophylaxis Hip replacement prophylaxis Hip fracture surgery prophylaxis Hip fracture surgery extended prophylaxis Lovenox is a registered trademark of sanofi-aventis U.S. LLC.. Prescribing Information for Lovenox (enoxaparin sodium injection). 7 ARIXTRA and Surgical Care Improvement Project (SCIP) SCIP: A Partnership for Better Care SCIP is a national quality partnership of organizations committed to improving the safety of surgical care through the reduction of postoperative complications VTE measures Recommended VTE prophylaxis ordered in surgery patients Appropriate VTE prophylaxis received within hours prior to surgery to hours after surgery ARIXTRA is included as an option for Hip fracture surgery General and gynecological surgery ARIXTRA is not FDA-approved for general and gynecological surgery. ARIXTRA is indicated for abdominal surgery in patients who are at risk for thromboembolic complications Elective total knee replacement surgery Elective total hip replacement surgery SCIP Goal: To reduce the incidence of surgical complications by % by. Surgical Care Improvement Project. Accessed July, 8.. SCIP VTE- and VTE-. %FPage%FQnetTier&c=Page. Accessed February,. 8 Once-daily Dosing Across All Indications for ARIXTRA Prophylaxis of VTE Patient weight kg* ARIXTRA daily dose. mg *Contraindicated for prophylaxis in patients < kg Treatment of PE and DVT Patient weight ARIXTRA daily dose < kg mg kg- kg 7. mg > kg mg Usual duration of administration with ARIXTRA is to 9 days Following hip fracture surgery, extended prophylaxis for up to additional days is recommended Simplified fixed dosing across a broad range of weights for treatment of PE and DVT Initiate warfarin within 7 hours after starting ARIXTRA and overlap therapies. ARIXTRA should be continued for at least days and until a therapeutic INR of. to. is reached Single-dose, prefilled syringes affixed with an automatic needle protection system 9
14 Important Safety Information WARNING: SPINAL/EPIDURAL HEMATOMAS Epidural or spinal hematomas may occur in patients who are anticoagulated with low molecular weight heparins (LMWH), heparinoids, or fondaparinux sodium and are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include: use of indwelling epidural catheters concomitant use of other drugs that affect hemostasis, such as nonsteroidal antiinflammatory drugs (NSAIDs), platelet inhibitors, or other anticoagulants a history of traumatic or repeated epidural or spinal puncture a history of spinal deformity or spinal surgery Monitor patients frequently for signs and symptoms of neurologic impairment. If neurologic compromise is noted, urgent treatment is necessary. Consider the benefit and risks before neuraxial intervention in patients anticoagulated or to be anticoagulated for thromboprophylaxis. Important Safety Information (cont d) CONTRAINDICATIONS ARIXTRA is contraindicated in the following conditions: Severe renal impairment (creatinine clearance < ml/min) in prophylaxis or treatment of venous thromboembolism. Active major bleeding. Bacterial endocarditis. Thrombocytopenia associated with a positive in vitro test for antiplatelet antibody in the presence of fondaparinux sodium. Body weight < kg (venous thromboembolism prophylaxis only). Important Safety Information (cont d) WARNINGS AND PRECAUTIONS Use with caution in patients who have conditions or who are taking concomitant medications that increase risk of hemorrhage. Bleeding risk is increased in renal impairment and in patients with low body weight. Thrombocytopenia can occur with administration of ARIXTRA. Periodic routine complete blood counts (including platelet counts), serum creatinine level, and stool occult blood tests are recommended The packaging (needle guard) contains dry natural rubber and may cause allergic reactions in latex sensitive individuals
15 Conclusions: ARIXTRA for the Treatment and Prophylaxis of VTE FDA approved for a broad range of indications Proven effective and has a low incidence of major bleeding -9 In the treatment of DVT and PE In VTE prophylaxis for patients undergoing major orthopedic surgery or abdominal surgery Simple once-daily dosing across all its indications in both inpatient and outpatient settings A nonheparin anticoagulant Based on both ACCP and SCIP guidelines, ARIXTRA is recommended as an option for VTE prophylaxis and treatment - *Major orthopedic surgery included elective hip replacement, hip fracture, and knee replacement surgeries.. Büller HR et al. N Engl J Med. ;9:9-7.. Büller HR et al. Ann Intern Med. ;: Turpie AG et al. Arch Intern Med. ;:8-8.. Eriksson BI et al. N Engl J Med. ;:98-.. Bauer KA et al. N Engl J Med. ;:-.. Lassen MR et al. Lancet. ;9: Turpie AG et al. Lancet. ;9: Agnelli G et al. Br J Surg. ;9:-. 9. Turpie et al. Int Soc Thromb Haemo. 7;:8-8.. Surgical Care Improvement Project. Accessed February,.. Hirsh et al. Chest. 8;:7S-9S.. Geerts et al. Chest. 8;:8S-S.
Objectives. Venous Thromboembolism (VTE) Prophylaxis. Case VTE WHY DO IT? Question: Who Is At Risk?
Objectives Venous Thromboembolism (VTE) Prophylaxis Rishi Garg, MD Department of Medicine Identify patients at risk for VTE Options for VTE prophylaxis Current Recommendations (based on The Seventh ACCP
More informationVenous Thromboembolism Prophylaxis: Checked!
Venous Thromboembolism Prophylaxis: Checked! William Geerts, MD, FRCPC Director, Thromboembolism Program, Sunnybrook HSC Professor of Medicine, University of Toronto National Lead, VTE Prevention, Safer
More information3/19/2012. What is the indication for anticoagulation? Has the patient previously been on warfarin? If so, what % of the time was the INR therapeutic?
Abigail E. Miller, PharmD, BCPS Clinical Specialist, Cardiology University of North Carolina Hospitals I have no personal financial relationships with the manufacturers of the products to disclose. Boehringer
More informationDEEP VEIN THROMBOSIS (DVT): TREATMENT
DEEP VEIN THROMBOSIS (DVT): TREATMENT OBJECTIVE: To provide an evidence-based approach to treatment of patients presenting with deep vein thrombosis (DVT). BACKGROUND: An estimated 45,000 patients in Canada
More informationTable 4. Efficacy of ARIXTRA Injection in the Prophylaxis of Thromboembolic Events Following Knee Replacement Surgery
Table 4. Efficacy of ARIXTRA Injection in the Prophylaxis of Thromboembolic Events Following Knee Replacement Surgery Endpoint Fondaparinux Sodium 2.5 mg SC 1 Enoxaparin Sodium 30 mg SC every 12 hours
More informationFatal P.E. Historic 1-2% Current %
Dr. (Prof.) Anil Arora MS (Ortho) DNB (Ortho) Dip SIROT (USA) FAPOA (Korea), FIGOF (Germany), FJOA (Japan) Commonwealth Fellow Joint Replacement (Royal National Orthopaedic Hospital, London, UK) Senior
More informationVenous Thromboembolism Prophylaxis
Approved by: Venous Thromboembolism Prophylaxis Vice President and Chief Medical Officer; and Vice President and Chief Operating Officer Corporate Policy & Procedures Manual Number: Date Approved January
More information10/8/2012. Disclosures. Making Sense of AT9: Review of the 2012 ACCP Antithrombotic Guidelines. Goals and Objectives. Outline
Disclosures Making Sense of AT9: Review of the 2012 ACCP Antithrombotic Guidelines No relevant conflicts of interest related to the topic presented. Cyndy Brocklebank, PharmD, CDE Chronic Disease Management
More informationNew Oral Anticoagulant Drugs in the Prevention of DVT
New Oral Anticoagulant Drugs in the Prevention of DVT Targets for Anticoagulants ORAL DIRECT VKAs inhibit the hepatic synthesis of several coagulation factors Rivaroxaban Apixaban Edoxaban Betrixaban X
More informationNOTE: The first appearance of terms in bold in the body of this document (except titles) are defined terms please refer to the Definitions section.
TITLE VENOUS THROMBOEMBOLISM PROPHYLAXIS SCOPE Provincial Acute and Sub-Acute Care Facilities APPROVAL AUTHORITY Alberta Health Services Executive Committee SPONSOR Vice President, Quality and Chief Medical
More informationTRANSPARENCY COMMITTEE OPINION. 18 April 2007
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 April 2007 ARIXTRA 2.5 mg/0.5 ml, solution for injection in prefilled syringe Pack of 2 (CIP: 359 225-4) Pack of
More informationFRAGMIN (dalteparin sodium injection) for Subcutaneous Use Only Initial U.S. Approval: 1994
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use FRAGMIN safely and effectively. See full prescribing information for FRAGMIN. FRAGMIN (dalteparin
More informationNew Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY
New Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY Fact VTE is deadly! It nibbles after it bites! The 30-day mortality rates for first-time DVT or
More informationAnticoagulation for prevention of venous thromboembolism
Anticoagulation for prevention of venous thromboembolism Original article by: Michael Tam Note: updated in June 2009 with the eighth edition (from the seventh) evidence-based clinical practice guidelines
More informationPerioperative VTE Prophylaxis
Perioperative VTE Prophylaxis Gregory J. Misky, M.D. Assistant Professor of Medicine University Of Colorado Denver You recommend the following 72 y.o. man admitted for an elective R hip repair. Patient
More informationVTE Management in Surgical Patients: Optimizing Prophylaxis Strategies
VTE Management in Surgical Patients: Optimizing Prophylaxis Strategies VTE in Surgical Patients: Recognizing the Patients at Risk Pathogenesis of thrombosis: Virchow s triad and VTE Risk Hypercoagulability
More informationSlide 1. Slide 2. Slide 3. Outline of This Presentation
Slide 1 Current Approaches to Venous Thromboembolism Prevention in Orthopedic Patients Hujefa Vora, MD Maria Fox, RN June 9, 2017 Slide 2 Slide 3 Outline of This Presentation Pathophysiology of venous
More informationChapter 1 Introduction
Chapter 1 Introduction There are several disorders which carry an increased risk of thrombosis, clots that interfere with normal circulation, including: venous thromboembolism (VTE), comprising both deep
More informationPrevention of Venous Thromboembolism
Prevention of Venous Thromboembolism Surgical Care Improvement Project Dale W. Bratzler, DO, MPH President and CEO Dale W. Bratzler, DO, MPH Oklahoma Foundation for Medical Quality QIOSC Medical Director
More informationMisunderstandings of Venous thromboembolism prophylaxis
Misunderstandings of Venous thromboembolism prophylaxis Veerendra Chadachan Senior Consultant Dept of General Medicine (Vascular Medicine and Hypertension) Tan Tock Seng Hospital, Singapore Case scenario
More informationVTE Prevention After Hip or Knee Replacement
This Clinical Resource gives subscribers additional insight related to the Recommendations published in May 2018 ~ Resource #340506 VTE Prevention After Hip or Knee Replacement The American College of
More informationDVT PROPHYLAXIS IN HOSPITALIZED MEDICAL PATIENTS SAURABH MAJI SR (PULMONARY,MEDICINE)
DVT PROPHYLAXIS IN HOSPITALIZED MEDICAL PATIENTS SAURABH MAJI SR (PULMONARY,MEDICINE) Introduction VTE (DVT/PE) is an important complication in hospitalized patients Hospitalization for acute medical illness
More informationLow Molecular Weight Heparin for Prevention and Treatment of Venous Thromboembolic Disorders
SURGICAL GRAND ROUNDS March 17 th, 2007 Low Molecular Weight Heparin for Prevention and Treatment of Venous Thromboembolic Disorders Guillermo Escobar, M.D. LMWH vs UFH Jayer s sales pitch: FALSE LMW is
More informationPRODUCT MONOGRAPH. fondaparinux sodium injection. 2.5 mg/0.5 ml 5.0 mg/0.4 ml 7.5 mg/0.6 ml 10.0 mg/0.8 ml. ATC Classification: B01AX05
PRODUCT MONOGRAPH Pr ARIXTRA fondaparinux sodium injection 2.5 mg/0.5 ml 5.0 mg/0.4 ml 7.5 mg/0.6 ml 10.0 mg/0.8 ml ATC Classification: B01AX05 Synthetic Antithrombotic Aspen Pharmacare Canada Inc 111
More informationDVT Pathophysiology and Prophylaxis in Medically Hospitalized Patients. David Liff MD Oklahoma Heart Institute Vascular Center
DVT Pathophysiology and Prophylaxis in Medically Hospitalized Patients David Liff MD Oklahoma Heart Institute Vascular Center Overview Pathophysiology of DVT Epidemiology and risk factors for DVT in the
More informationDENOMINATOR: All surgical patients aged 18 years and older undergoing procedures for which VTE prophylaxis is indicated in all patients
Measure #23 (NQF 0239): Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients) National Quality Strategy Domain: Patient Safety 2017 OPTIONS FOR INDIVIDUAL MEASURES:
More informationVenous thrombosis is common and often occurs spontaneously, but it also frequently accompanies medical and surgical conditions, both in the community
Venous Thrombosis Venous Thrombosis It occurs mainly in the deep veins of the leg (deep vein thrombosis, DVT), from which parts of the clot frequently embolize to the lungs (pulmonary embolism, PE). Fewer
More informationINDICATIONS FOR THROMBO-PROPHYLAXIS AND WHEN TO STOP ANTICOAGULATION BEFORE ELECTIVE SURGERY
INDICATIONS FOR THROMBO-PROPHYLAXIS AND WHEN TO STOP ANTICOAGULATION BEFORE ELECTIVE SURGERY N.E. Pearce INTRODUCTION Preventable death Cause of morbidity and mortality Risk factors Pulmonary embolism
More informationCPT only copyright 2014 American Medical Association. All rights reserved. 12/23/2014 Page 66 of 593
Measure #23 (NQF 0239): Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients) National Quality Strategy Domain: Patient Safety 2015 PQRS OPTIONS FOR INDIVIDUAL MEASURES:
More informationTHROMBOPROPHYLAXIS: NON-ORTHOPEDIC SURGERY
THROMBOPROPHYLAXIS: NON-ORTHOPEDIC SURGERY OBJECTIVE: To outline a practical approach for the prevention of venous thromboembolism (VTE) in patients undergoing non-orthopedic surgery. BACKGROUND: VTE is
More informationChallenges in Anticoagulation and Thromboembolism
Challenges in Anticoagulation and Thromboembolism Ethan Cumbler M.D. Assistant Professor of Medicine Hospitalist Medicine Section University of Colorado Denver May 2010 No Conflicts of Interest Objectives
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #23 (NQF 0239): Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients) National Quality Strategy Domain: Patient Safety 2018 OPTIONS FOR INDIVIDUAL MEASURES:
More informationVTE in the Trauma Population
VTE in the Trauma Population Erik Peltz, D.O. February 11 th, 2015 * contributions from Eduardo Gonzalez, M.D. University of Colorado T-32 Research Fellow The problem. VTE - Scope of the Problem One of
More informationTitle: Low Molecular Weight Heparins (LMWH), fondaparinux (Arixtra)
Origination: 03/29/05 Revised: 09/01/10 Annual Review: 11/20/13 Purpose: To provide guidelines and criteria for the review and decision determination of requests for medications that requires prior authorization.
More informationResults from RE-COVER RE-COVER II RE-MEDY RE-SONATE EXECUTIVE SUMMARY
Assessment of the safety and efficacy of dabigatran etexilate (Pradaxa ) in the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT and PE Results from
More informationNew Antithrombotic and Antiplatelet Drugs in CAD : (Factor Xa inhibitors, Direct Thrombin inhibitors and Prasugrel)
New Antithrombotic and Antiplatelet Drugs in CAD : (Factor Xa inhibitors, Direct Thrombin inhibitors and Prasugrel) Limitations and Advantages of UFH and LMWH Biological limitations of UFH : 1. immune-mediated
More informationIs Oral Rivaroxaban Safe and Effective in the Treatment of Patients with Symptomatic DVT?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 1-1-2013 Is Oral Rivaroxaban Safe and Effective
More informationDirect Oral Anticoagulants (DOACs). Dr GM Benson Director NI Haemophilia Comprehensive Care Centre and Thrombosis Unit BHSCT
Direct Oral Anticoagulants (DOACs). Dr GM Benson Director NI Haemophilia Comprehensive Care Centre and Thrombosis Unit BHSCT OAC WARFARIN Gold standard DABIGATRAN RIVAROXABAN APIXABAN EDOXABAN BETRIXABAN
More informationEffect of fondaparinux 2.5 mg once daily on mortality: a meta-analysis of phase III randomized trials of venous thromboembolism prevention
European Heart Journal Supplements (2008) 10 (Supplement C), C8 C13 doi:10.1093/eurheartj/sun004 Effect of fondaparinux 2.5 mg once daily on mortality: a meta-analysis of phase III randomized trials of
More informationAre guidelines for anticoagulation useful in cancer patients?
Session 3 Striking a Balance Between Bleeding and the Risk of Thrombosis in Cancer Patients Are guidelines for anticoagulation useful in cancer patients? Sebastian Szmit Department of Pulmonary Circulation
More informationMeasure #23 (NQF 0239): Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients)
Measure #23 (NQF 0239): Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients) 2013 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY DESCRIPTION: Percentage
More information1. SCOPE of GUIDELINE:
Page 1 of 35 CLINICAL PRACTICE GUIDELINE: Venous Thromboembolism (VTE) Prevention Guideline: Thromboprophylaxis AUTHORIZATION: VP, Medicine Date Approved: May 17, 2012 Date Revised: Vancouver Coastal Health
More informationGetting Started Kit VENOUS THROMBOEMBOLISM PREVENTION. Section 2: Evidence-Based Appropriate VTE Prophylaxis
Reducing Harm Improving Healthcare Protecting Canadians VENOUS THROMBOEMBOLISM PREVENTION Getting Started Kit Section 2: Evidence-Based Appropriate VTE Prophylaxis January 2017 www.patientsafetyinstitute.ca
More informationOutpatient Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin (LMWH) Clinical Practice Guideline August 2015
Outpatient Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin (LMWH) Clinical Practice Guideline August 2015 General Principles: There is compelling data in the medical literature to support
More informationTransitions of care in anticoagulated patients
Journal of Multidisciplinary Healthcare open access to scientific and medical research Open Access Full Text Article Transitions of care in anticoagulated patients Expert Opinion Franklin Michota Department
More informationPRODUCT MONOGRAPH. (Enoxaparin sodium solution for injection, manufacturer s standard) 150 mg/ml. 120 mg/0.8 ml
PRODUCT MONOGRAPH Pr LOVENOX (Enoxaparin sodium solution for injection, manufacturer s standard) 100 mg/ml 30 mg/0.3 ml 40 mg/0.4 ml 60 mg/0.6 ml 80 mg/0.8 ml 100 mg/ml 300 mg/3 ml Pr LOVENOX HP (Enoxaparin
More informationClinical Policy: Dalteparin (Fragmin) Reference Number: ERX.SPA.207 Effective Date:
Clinical Policy: (Fragmin) Reference Number: ERX.SPA.207 Effective Date: 01.11.17 Last Review Date: 02.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationPULMONARY EMBOLISM (PE): DIAGNOSIS AND TREATMENT
PULMONARY EMBOLISM (PE): DIAGNOSIS AND TREATMENT OBJECTIVE: To provide a diagnostic algorithm and treatment options for patients with acute pulmonary embolism (PE). BACKGROUND: Venous thromboembolism (VTE)
More information30 mg single intravenous bolus plus a 1 mg/kg subcutaneous dose followed by 1 mg/kg subcutaneously every 12 hours
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use safely and effectively. See full prescribing information for. (enoxaparin sodium injection), for
More informationCANCER ASSOCIATED THROMBOSIS. Pankaj Handa Department of General Medicine Tan Tock Seng Hospital
CANCER ASSOCIATED THROMBOSIS Pankaj Handa Department of General Medicine Tan Tock Seng Hospital My Talk Today 1.Introduction 2. Are All Cancer Patients at Risk of VTE? 3. Should All VTE Patients Be Screened
More informationVenous Thromboembolism Prophylaxis After Major Orthopaedic Surgery: A Pooled Analysis of Randomized Controlled Trials
Winner of the AAHKS Award Venous Thromboembolism Prophylaxis After Major Orthopaedic Surgery: A Pooled Analysis of Randomized Controlled Trials Greg A. Brown, MD, PhD The Journal of Arthroplasty Vol. 24
More informationPREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM
PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM International Consensus Statement 2013 Guidelines According to Scientific Evidence Developed under the auspices of the: Cardiovascular Disease Educational
More informationJessica Bryan, Natalia Evans, Karlyn Henderson, & Whitney Parks
Jessica Bryan, Natalia Evans, Karlyn Henderson, & Whitney Parks 1. What is the most common cause of death in hospitalized patients? 1. Hospital-acquired infection 2. Pulmonary embolism 3. Myocardial infarction
More informationThe Treatment of Venous Thromboembolism (VTE): Has Warfarin Met Its Match? Michael P. Gulseth, Pharm. D., BCPS, FASHP Program Director for
The Treatment of Venous Thromboembolism (VTE): Has Warfarin Met Its Match? Michael P. Gulseth, Pharm. D., BCPS, FASHP Program Director for Anticoagulation Services Sanford USD Medical Center Sioux Falls,
More informationEXTENDING VTE PROPHYLAXIS IN ACUTELY ILL MEDICAL PATIENTS
EXTENDING VTE PROPHYLAXIS IN ACUTELY ILL MEDICAL PATIENTS Samuel Z. Goldhaber, MD Director, VTE Research Group Cardiovascular Division Brigham and Women s Hospital Professor of Medicine Harvard Medical
More informationVenous Thrombo-Embolism. John de Vos Consultant Haematologist RSCH
Venous Thrombo-Embolism John de Vos Consultant Haematologist RSCH overview The statistics Pathogenesis Prophylaxis Treatment Agent Duration Incidental VTE Recurrence of VTE IVC filters CVC related thrombosis
More information10/24/2013. Heparin-Induced Thrombocytopenia (HIT) Anticoagulation Management in ECMO Therapy:
Anticoagulation Management in ECMO Therapy: Heparin-Induced (HIT) Michael H. Creer, MD Professor of Pathology Director, Clinical Laboratories, Medical Co- Director, Hematopathology and Chief, Division
More informationClinical Policy: Dalteparin (Fragmin) Reference Number: ERX.SPA.207 Effective Date:
Clinical Policy: (Fragmin) Reference Number: ERX.SPA.207 Effective Date: 01.11.17 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationPrevention and management of deep venous thrombosis (DVT) John Fletcher Wound Care Association of New South Wales
Prevention and management of deep venous thrombosis (DVT) John Fletcher Wound Care Association of New South Wales Merimbula, 6 th November 2010 University of Sydney Department of Surgery Westmead Hospital
More informationXarelto (rivaroxaban) Prescriber Guide
Xarelto (rivaroxaban) Prescriber Guide October 2018 PP-XAR-IE-0031 Contents Patient Alert Card 4 Dosing Recommendations 4 Stroke prevention in adult patients with non-valvular atrial fibrillation 4 Patients
More informationSupplementary Online Content
Supplementary Online Content Mismetti P, Laporte S, Pellerin O, Ennezat P-V, Couturaud F, Elias A, et al. Effect of a retrievable inferior vena cava filter plus anticoagulation vs anticoagulation alone
More informationInhixa (Enoxaparin Sodium)
Inhixa (Enoxaparin Sodium) P R E V ENTIS SAFETY D E V I C E P R E V E N T I S I S A N AU TO M AT I C N E E D L E S H I E L D I N G S Y S T E M, W H I C H H A S A C O V E R T H AT E X T E N D S O V E R
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Arixtra 1.5 mg/0.3 ml solution for injection, pre-filled syringe. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each pre-filled
More informationAspirin as Venous Thromboprophylaxis
Canadian Society of Internal Medicine Nov 2, 2017 Aspirin as Venous Thromboprophylaxis Bill Geerts, MD, FRCPC Thromboembolism Consultant, Sunnybrook HSC Professor of Medicine, University of Toronto Disclosures
More informationHow long to continue anticoagulation after DVT?
How long to continue anticoagulation after DVT? Dr. Nihar Ranjan Pradhan M.S., DNB (Vascular Surgery), FVES(UK) Consultant Vascular Surgeon Apollo Hospital, Jubilee Hills, Hyderabad (Formerly Faculty in
More informationWhat s new with DOACs? Defining place in therapy for edoxaban &
What s new with DOACs? Defining place in therapy for edoxaban & Use of DOACs in cardioversion Caitlin M. Gibson, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy University of North Texas
More informationVenous Thromboembolism National Hospital Inpatient Quality Measures
Venous Thromboembolism National Hospital Inpatient Quality Measures Presentation Overview Review venous thromboembolism as a new mandatory measure set Outline measures with exclusions and documentation
More informationThe legally binding text is the original French version. Opinion 15 May 2013
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 15 May 2013 ARIXTRA 2.5 mg/0.5 ml, solution for injection in pre-filled syringe B/2 (CIP: 34009 359 225 4 0) B/7 (CIP:
More informationMabel Labrada, MD Miami VA Medical Center
Mabel Labrada, MD Miami VA Medical Center *1-Treatment for acute DVT with underlying malignancy is for 3 months. *2-Treatment of provoked acute proximal DVT can be stopped after 3months of treatment and
More informationVenous Thromboembolism. Prevention
Venous Thromboembolism Prevention August 2010 Venous Thromboembloism Prevention 1 1 Expected Practice Assess all patients upon admission to the ICU for risk factors of venous thromboembolism (VTE) and
More informationNew Age Anticoagulants: Bleeding Considerations
Ontario Regional Blood Coordinating Network March 23, 2012 New Age Anticoagulants: Bleeding Considerations Bill Geerts, MD, FRCPC Thromboembolism Specialist, Sunnybrook HSC Professor of Medicine, University
More informationPrimary VTE Thromboprophylaxis
Primary VTE Thromboprophylaxis Controversies in Hematology 53 rd Annual Meeting of Thai Society of Hematology Bundarika Suwanawiboon, MD Division of Hematology Department of Medicine Faculty of Medicine
More informationSupra-Regional Audit Anticoagulation in Palliative Care. 4 th March Denise Farrance
Supra-Regional Audit Anticoagulation in Palliative Care 4 th March 2010 Dr Helen Emms Dr Carolyn Watt Denise Farrance Dr Richard Latten Dr Leslie Johnny Overview Review of current standard & guidelines
More informationUPDATE ON TREATMENT OF ACUTE VENOUS THROMBOSIS
UPDATE ON TREATMENT OF ACUTE VENOUS THROMBOSIS Armando Mansilha MD, PhD, FEBVS 16 th National Congress of the Italian Society of Vascular and Endovascular Surgery Bologna, 2017 Disclosure I have the following
More informationGeneral. Recommendations. Guideline Title. Bibliographic Source(s) Guideline Status. Major Recommendations
General Guideline Title Prevention of deep vein thrombosis and pulmonary embolism. Bibliographic Source(s) American College of Obstetricians and Gynecologists (ACOG). Prevention of deep vein thrombosis
More informationClinical issues which drug for which patient
Anticoagulants - a matter of heart! Towards a bright future? Clinical issues which drug for which patient Sabine Eichinger Dept. of Medicine I Medical University of Vienna/Austria Conflicts of interest
More informationP-RMS: LT/H/PSUR/0004/001
Core Safety Profile Active substance: Dalteparine Pharmaceutical form(s)/strength: Solution for injection, 2500 I.U./0.2ml, 2500 I.U./ml, 5000 I.U./0.2ml, 7500 I.U./0.3ml, 7500 I.U./0.75ml, 10000 I.U./0.4ml,
More informationCLINICAL BRIEFS. Enoxaparin Versus Unfractionated Heparin With Fibrinolysis for ST-elevation Myocardial Infarction. Clinical Insights into
CLINICAL BRIEFS Clinical Insights into Enoxaparin Versus Unfractionated Heparin With Fibrinolysis for ST-elevation Myocardial Infarction Elliott M. Antman, MD, David A. Morrow, MD, MPH, Carolyn H. McCabe,
More informationProthrombin Complex Concentrate- Octaplex. Octaplex
Prothrombin Complex Concentrate- Concentrated Factors Prothrombin Complex Concentrate (PCC) 3- factor (factor II, IX, X) 4-factor (factors II, VII, IX, X) Activated 4-factor (factors II, VIIa, IX, X) Coagulation
More informationAspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty: The EPCAT II Trial
Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty: The EPCAT II Trial Wednesday, June 6, 2018, 2:00PM ET Guest Author: David R. Anderson, MD Presenter: Sara Vazquez, PharmD Moderators:
More informationARTEMIS. ARixtra (fondaparinux) for ThromboEmbolism prevention in. a Medical Indications Study. NV Organon Protocol 63129
ARTEMIS ARixtra (fondaparinux) for ThromboEmbolism prevention in NV Organon Protocol 63129 a Medical Indications Study Objective To demonstrate efficacy and to assess safety of oncedaily subcutaneous (SC)
More informationDebate: New Generation Anti-Coagulation Agents are a Better Choice than Warfarin in the Management of AF
Debate: New Generation Anti-Coagulation Agents are a Better Choice than Warfarin in the Management of AF Bradley P. Knight, MD Director of Cardiac Electrophysiology Bluhm Cardiovascular Institute Northwestern
More informationPatients with cancer are at a greater risk of developing venous thromboembolism than non-cancer patients, partly due to the 1
CANCER ASSOCIATED THROMBOSIS TREATMENT Patients with cancer are at a greater risk of developing venous thromboembolism than non-cancer patients, partly due to the 1 ability of tumour cells to activate
More informationMeasurement and Improvement of Quality of Cardiovascular Care DR : DEHESTANI
Measurement and Improvement of Quality of Cardiovascular Care DR : DEHESTANI Hospitals For hospitals in the United States, measures of cardiovascular care mandated by the Joint Commission have recently
More informationReversal of Novel Oral Anticoagulants. Angelina The, MD March 22, 2016
Reversal of Novel Oral Anticoagulants Angelina The, MD March 22, 2016 Argatroban Bivalirudin Enoxaparin Lepirudin Heparin Dabigatran Apixaban 1939 1954 1998 2000 1999 2001 10/2010 7/2011 12/2012 1/2015
More informationEarly Ambulation Reduces the Risk of Venous Thromboembolism After Total Knee Replacement. Marilyn Szekendi, PhD, RN
Early Ambulation Reduces the Risk of Venous Thromboembolism After Total Knee Replacement Marilyn Szekendi, PhD, RN ANA 7 th Annual Nursing Quality Conference, February 2013 Research Team Banafsheh Sadeghi,
More informationNew Anticoagulants Therapies
New Anticoagulants Therapies Rachel P. Rosovsky, MD, MPH October 22, 2015 Conflicts of Interest No disclosures 2 Agenda 3 Historical perspective Novel oral anticoagulants Stats Trials Approval Concerns/Limitations
More informationBMS Project ID: 432US /16
The Bristol-Myers Squibb/Pfizer Medical Alliance would like to inform you that the following sections of the prescribing information for ELIQUIS (apixaban) have been updated and the underlined text denotes
More informationDisclosure. Objectives. New Anticoagulants 6/5/2014 GHASSAN HADDAD M.D FHM. South Miami hospital Director of the Anticoagulation clinic.
/5/1 New Anticoagulants: Opportunities, Challenges and Practical Considerations GHASSAN HADDAD M.D FHM. Chief of Hospital Medicine i South Miami hospital Director of the Anticoagulation clinic. Financial
More informationObesity, renal failure, HIT: which anticoagulant to use?
Obesity, renal failure, HIT: which anticoagulant to use? Mark Crowther with thanks to Dr David Garcia and others. This Photo by Unknown Author is licensed under CC BY-SA 1 2 Drug choices The DOACs have
More informationUnderstanding Best Practices in Anticoagulation Therapy in Patients with Venous Thromboembolism. Rajat Deo, MD, MTR
Understanding Best Practices in Anticoagulation Therapy in Patients with Venous Thromboembolism Rajat Deo, MD, MTR Director of Translational Research in Cardiac Arrhythmias Division of Cardiovascular Medicine
More informationPRODUCT MONOGRAPH. Pr FRAGMIN. Dalteparin Sodium Injection
PRODUCT MONOGRAPH Pr FRAGMIN Dalteparin Sodium Injection Solution 10 000 IU (anti-factor Xa)/1 ml, Ampoule 25 000 IU (anti-factor Xa)/mL 3.8 ml, Multi-Dose Vial 2500 IU (anti-factor Xa)/mL 4 ml, Single-Dose
More informationThe clinical relevance of AMPLIFY programme
Venice October 16th 2015 The clinical relevance of AMPLIFY programme Francesco Dentali Department of Clinical Medicine Insubria University Varese Disclosures Bayer Bristol-Myers Squibb/Pfizer Boehringer
More informationHEPARIN-INDUCED THROMBOCYTOPENIA (HIT)
HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) OBJECTIVE: To assist clinicians with the investigation and management of suspected and documented heparin-induced thrombocytopenia (HIT). BACKGROUND: HIT is a transient,
More informationThere are many advantages of spinal or epidural analgesia/anesthesia
PERIODICUM BIOLOGORUM UDC 57:61 VOL. 115, No 2, 125 130, 2013 CODEN PDBIAD ISSN 0031-5362 Overview Controversies in regional anaesthesia patient on anticoagulant therapy BRANKO TRIPKOVI] Department of
More informationPrimary VTE Prophylaxis. Ponlapat Rojnuckarin, MD PhD Chulalongkorn University Bangkok, Thailand
Primary VTE Prophylaxis Ponlapat Rojnuckarin, MD PhD Chulalongkorn University Bangkok, Thailand A 70-yr-old female before THA BMI 31 kg/m 2 with varicose vein What do you recommend for VTE prevention?
More informationThis chapter will describe the effectiveness of antithrombotic
Antithrombotic Therapy for Venous Thromboembolic Disease The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Harry R. Büller, MD, Chair; Giancarlo Agnelli, MD; Russel D. Hull, MBBS,
More informationClinical Guideline for Anticoagulation in VTE
Clinical Guideline for Anticoagulation in VTE These clinical guidelines are intended to provide evidence-based recommendations regarding the anticoagulation in patients with DVT and PE. Please note that
More information